BR0302832A - Uso de compostos tendo a atividade biológica de peptìdeo intestinal vasoativo para o tratamento de doença pulmonar obstrutiva crÈnica - Google Patents

Uso de compostos tendo a atividade biológica de peptìdeo intestinal vasoativo para o tratamento de doença pulmonar obstrutiva crÈnica

Info

Publication number
BR0302832A
BR0302832A BR0302832-1A BR0302832A BR0302832A BR 0302832 A BR0302832 A BR 0302832A BR 0302832 A BR0302832 A BR 0302832A BR 0302832 A BR0302832 A BR 0302832A
Authority
BR
Brazil
Prior art keywords
treatment
chronic obstructive
peptides
intestinal peptide
compounds
Prior art date
Application number
BR0302832-1A
Other languages
English (en)
Inventor
Dorian Bevec
Original Assignee
Mondobiotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Sa filed Critical Mondobiotech Sa
Publication of BR0302832A publication Critical patent/BR0302832A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE COMPOSTOS TENDO A ATIVIDADE BIOLóGICA DE PEPTìDEO INTESTINAL VASOATIVO PARA O TRATAMENTO DE DOENçA PULMONAR OBSTRUTIVA CRÈNICA". A presente invenção refere-se ao uso de peptídeos e composições farmacêuticas contendo os ditos peptídeos, que são altamente ativos biológica e farmacologicamente como drogas terapêuticas para o tratamento de doenças relacionadas à doença pulmonar obstrutiva crónica (COPD), que está preferivelmente não relacionada a sintomas de hipertensão pulmonar. Além disso, a invenção mostra o uso dos ditos peptídeos para uma outra doença de pulmão que é síndrome de sofrimento respiratório aguda (adulto) (ARDS). Pode ser mostrado que os peptídeos conhecidos ocorrendo naturalmente "peptídeo intestinal vasoativo (VIP)" e "polipeptídeo de ativação de adenilato ciclase de pituitária (PACAP)", assim como análogos ou derivados de VIP e PACAP, podem ser usados com sucesso para o tratamento das ditas doenças.
BR0302832-1A 2002-01-26 2003-01-23 Uso de compostos tendo a atividade biológica de peptìdeo intestinal vasoativo para o tratamento de doença pulmonar obstrutiva crÈnica BR0302832A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001839 2002-01-26
PCT/CH2003/000056 WO2003061680A2 (en) 2002-01-26 2003-01-23 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
BR0302832A true BR0302832A (pt) 2004-04-27

Family

ID=27589068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0302832-1A BR0302832A (pt) 2002-01-26 2003-01-23 Uso de compostos tendo a atividade biológica de peptìdeo intestinal vasoativo para o tratamento de doença pulmonar obstrutiva crÈnica

Country Status (5)

Country Link
EP (1) EP1468021A2 (pt)
BR (1) BR0302832A (pt)
CA (1) CA2472270A1 (pt)
NO (1) NO20034269L (pt)
WO (1) WO2003061680A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE432079T1 (de) 2003-07-14 2009-06-15 Mondobiotech Ag Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US9006181B2 (en) * 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
CA2779496A1 (en) 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
EP3583933A1 (en) 2018-06-20 2019-12-25 Albert-Ludwigs-Universität Freiburg Administration of aviptadil by inhalation to treat chronic beryllium disease
BR112021022170A2 (pt) 2019-05-07 2021-12-21 Advita Lifescience Gmbh Peptídeo intestinal vasoativo (vip) para uso no tratamento de pneumonite induzida por fármacos
EP4232073B1 (en) 2020-12-04 2024-05-01 Centurion Ilac Sanayi Ve Ticaret Anonim Sirketi New dosage regimen for inhaled vasoactive intestinal polypeptide
WO2022224172A1 (en) * 2021-04-20 2022-10-27 Advita Lifescience Ag Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612314A (en) * 1995-04-21 1997-03-18 Brigham & Women's Hospital Nitrosylated neuropeptides
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
CA2428552A1 (en) * 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension

Also Published As

Publication number Publication date
NO20034269D0 (no) 2003-09-24
WO2003061680A3 (en) 2003-11-13
WO2003061680A9 (en) 2004-06-03
CA2472270A1 (en) 2003-07-31
NO20034269L (no) 2003-11-26
EP1468021A2 (en) 2004-10-20
WO2003061680A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
ES2647418T3 (es) Derivados de exendina-4 como agonistas dobles de GLP1/glucagón
AU2006203749B2 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
ES2621864T3 (es) Fragmentos de VIP y usos de los mismos
EP0692971A1 (en) Analogs of peptide yy and uses thereof
US6110892A (en) Parathyroid hormone analogues for the treatment of osteoporosis
JP2002509078A (ja) エキセンジンおよびｇｌｐ−１の変力および利尿効果
JP2002523424A (ja) 新規な抗糖尿病ペプチド
ZA200607492B (en) Y2/Y4 selective receptor agonists for therapeutic interventions
EP0915911B1 (en) Parathyroid hormone analogues for the treatment of osteoporosis
BR0302832A (pt) Uso de compostos tendo a atividade biológica de peptìdeo intestinal vasoativo para o tratamento de doença pulmonar obstrutiva crÈnica
Rattan et al. Structure-activity relationship of subtypes of cholecystokinin receptors in the cat lower esophageal sphincter
JP2000505105A (ja) ペプチドｙｙのアナログおよびその使用
NO330954B1 (no) Anvendelse av en forbindelse for fremstilling av et legemiddel for behandling av en pasient som lider av sarkoidose.
US9725484B2 (en) Methods and compositions for the treatment of bone remodeling disorders
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
WO2005014030A1 (en) Method for treating lung diseases associated with ventilation-perfusion mismatches
CA2326146A1 (en) Template associated npy y2-receptor agonists
ES2356595T3 (es) Nuevos compuestos de actividad mixta de la amilina.
EP4138905A1 (en) Use of surfactant protein d to treat viral infections
US10494405B2 (en) Methods and compositions for the treatment of arthritis
US20240115567A1 (en) Small therapeutic molecules capable of inhibiting the catalytic activity of the main protease enzyme of sars-cov-2
Nustede et al. On the effect of xenin and xenin fragments on exocrine pancreas secretion in vivo
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
AU2003201287A1 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired